Table 2.
Recently delivered women: Receipt and use of misoprostol for PPH prevention: % (n)
| Mountain region | Hill region | Terai region | P-valuea | |
| (n = 690) | (n = 690) | (n = 690) | ||
| Received information during pregnancy | 9.7 (67) | 19.3 (133) | 15.2 (105) | <0.001 |
| Received misoprostol during pregnancy | 7.5 (52) | 17.3 (119) | 12.9 (89) | <0.001 |
| Among those who received misoprostol | n = 52 | n = 119 | n = 89 | |
| Source of misoprostol | 0.005 | |||
| FCHV | 80.8 (42) | 78.2 (93) | 94.4 (84) | |
| Health facility provider | 17.3 (9) | 21.0 (25) | 5.6 (5) | |
| Friend/family | 1.9 (1) | 0.8 (1) | 0.0 (0) | |
| Used misoprostol for PPH prevention | 48.1 (25) | 45.4 (54) | 31.5 (28) | 0.069 |
| Among those who used misoprostol | n = 25 | n = 54 | n = 28 | |
| Used all 3 tablets | 84.0 (21) | 90.7 (49) | 92.9 (26) | 0.641 |
| Used immediately after delivery of baby | 80.0 (20) | 75.9 (41) | 64.3 (18) | 0.391 |
| Used misoprostol correctlyb | 68.0 (17) | 72.2 (39) | 64.3 (18) | 0.764 |
| Would recommend miso to others (n = 98) | 100.0 (25) | 100.0 (47) | 96.2 (25) | 0.520 |
aWe used Pearson’s Chi-Square and Fisher’s Exact tests (2-sided) to assess the significance of regional differences
bCorrect use was defined as taking all 3 tablets immediately after delivery of baby and prior to placental delivery